Kyle Guse
Chief Financial Officer, Atossa Therapeutics (United States).
Companies
- Plus TherapeuticsBoard member Aug 15, 2025 to now1
- Atossa Therapeutics (United States)Chief financial officer Jan 10, 2013 to Mar 6, 20232
- Atossa Therapeutics (United States)Officer Mar 18, 2015 to Mar 18, 20153
- Atossa Therapeutics (United States)General counsel Jan 10, 2013 to May 8, 20142
Holdings
Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.
Shares held
Plus Therapeutics CNSY922 shares4$1.6K at $1.70Jul 1, 2026
As of each latest filing. The line shows shares held over time.
Recent filings
- Jul 1, 2026Exercised options 922 shares of Plus Therapeutics4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARPlus Therapeutics, Board member
- 2
- 3
- 4